Recent Advancement in Topical Drug Delivery for Psoriasis: Clinical Perti-nence and Potential Market

Psoriasis is an immune-mediated chronic skin inflammation. This disease can be associated with several manifestations like red flakes, silver scales, patches, plaques, and silvery-white squams. Approximately 70% of the patients treated with topical dosage forms have a mild-to-moderate form of psoriasis, whereas a moderate-to-severe form of psoriasis is treated with systemic, photo, and biological therapies. Considering the big fraction that topicals cover, we present the current market potential, clinical relevance, and recent advances in the topical delivery of the drug for psoriasis. Though we witnessed several advancements in the recent few decades, delivering new immunomodulatory and biological molecules for topical psoriatic treatment have been proven to be efficient and safe options for the large percentage of patients for whom systemic therapy is not indicated. This article enumerates the promising topical dosage forms at present under assessment for their clinical pertinence. The competency of conventional topicals to reach and transform the world market is enumerated in terms of their success rate after proving the clinical pertinence against psoriasis. However, the entrance of novel drug delivery systems based on advanced topical products in the global market is highly anticipated as they have immense potential to impact the psoriasis treatment in the near future.